| CASE REPORT |
|
| Year : 2021 | Volume
: 31
| Issue : 3 | Page : 303-306 |
Association of acute interstitial nephritis with nivolumab in renal cell carcinoma: A case report
Befa Noto-Kadou-Kaza, Geoffroy Desbuissons, Corinne Bagnis Isnard
Department of Nephrology, Pitie-Salpetriere, 47-80 Boulevard de l'Hôpital, 75013, Paris, France
Correspondence Address:
Dr. Befa Noto-Kadou-Kaza
Department of Nephrology, Pitie-Salpetriere, 47-80 Boulevard de l'Hôpital, 75013, Paris
France
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijn.IJN_62_20
Recently, a number of innovative anticancer agents such us the programmed death 1 (PD-1) immune checkpoint inhibitors have been developed. Nevertheless, this type of immunotherapy may be associated with immune-related adverse events whose pathophysiology is considered similar to those found in autoimmune diseases such as nephritis. We report the case of a 71-year-old female with metastatic renal carcinoma who underwent nephrectomy. After three lines of other chemotherapies (VEGF and mTOR inhibitors), the patient was treated by nivolumab (3 mg/kg) for 4 months and developed acute kidney injury 16 weeks after initiating this immunotherapy. Kidney biopsy displayed a diffuse extensive interstitial inflammation associated with moderate interstitial edema. The discontinuation of nivolumab and the administration of prednisone (at 1 mg/kg and tapered over 3 months) was an effective treatment of the interstitial edema and led to the recovery of the kidney function.
[FULL TEXT] [PDF]*
|
|
Editorial Board
